BioSpace News Archive

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2022 and provided a business update.

Impel Pharmaceuticals Inc. announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 5:00 p.m. ET in Miami, Florida.

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended March 31, 2022 and provided a company update.

Medable Inc., the leading software provider for patient-centered clinical trials, announced that Alison Holland, Medable’s Head of Decentralized Trials, will participate in the Prix Galien UK 2022 Forum & Awards Ceremony.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.

AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development.

MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), today announced that the first patient has been randomized and dosed, in a U.S. site, in its global Phase 2 clinical trial evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS).

Adagene Inc. announced that members of the company’s management will participate in the following upcoming investor conferences.

LAVA Therapeutics N.V. announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for LAVA-051, the Company’s lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and highlighted recent business updates.